Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...

CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.